Support and advise management team and Board on key strategic projects

atai is a biotech company that operates through minority and majority investments in health technology portfolio companies (public and private). I am accountable for - overall Corporate Strategy, New Investments and Portfolio management, Early Commercial Planning and Strategic Communications. Since joining atai I have delivered -
• Through an ongoing review of its portfolio, I have evolved atai's investment and asset mix to respond to changing capital markets environment, growing capital needs for clinical development and ensuring that atai's catalyst calendar remains attractive – trimmed the portfolio from a pipeline of 11+ assets to 4 later-stages ones
• Four (4) public and private company Board Director positions to progress portfolio through clinical development and external partnering activities
• Lead 4 total investments including 1 new equity investment in a Ph2 private company (details in deal sheet) with strong shareholder rights helping achieve atai's long term strategic goals
• Built out early commercial function to ensure that clinical evidence and TPP being generated at an asset level is able to optimize commercial outcomes – for both prescribers, payers and health care system
• My role further evolved to take on additional financing strategy responsibility – core part of financing discussions with public markets investors (for ATAI TopCo) and private investors (as a part of subsidiary management) –
• partner with subsidiary CEOs to plan financing strategy

Reporting to the CEO, North America and Global Pharmaceutical Business I held overall responsibility for all Business Development, licensing activities future pipeline strategy for Otsuka globally.
• Shaped, evolved and executed on the Business Development strategy and plans; Acted as the central anchor point for various aspects of the corporate and pipeline strategy – research, development and commercial
• Built and led global team of ~36 FTEs across S&E, Commercial evaluation, Transactions, Digital BD and Alliance Management; teams located across US, Europe and Japan
• Therapy areas of focus were CNS, Immunology, Rare disease, Kidney disorders, Hematology, Oncology; instrumental for shaping a specific growth strategy in kidney disease and an entry strategy for Immunology
• As co-chair of the Global BD Steering Committee, worked closely with the Board of Directors and the ELT to ensure that corporate goals for the longer-term growth of the pipeline and various commercial franchises are met
• Ensured high influence and strong relationships with leadership team members and other internal and external stakeholders to continuously monitor and evolve BD priorities to be in-line with Global corporate priorities
• Evolved Global BD organization including senior colleagues in Japan to move towards a more flexible, innovative and agile approach to partnering and transactions including the setting up of a small investment fund

Set up and led Otsuka's strategic Business Development effort in Europe and was responsible for investment and partnering for pharmaceutical and digital health opportunities.
Dr. (continued)
• Managed a team of pharma / biotech and digital health opportunity BD leads (S&E and transactions)
• Led on deal structuring, term sheets and contract negotiations
• Performed scientific and commercial assessments of new opportunities while operating within the matrix of a large company, including close, regular interactions with senior management across Otsuka regions; coordinating the deal process, due-diligence and data room management, financial analysis, term sheets and contract negotiations
• Represented Otsuka externally through relationships with VCs, other pharma and a strong network
• Commercial Director, Europe and other market access/commercial roles. (April 2014 – October 2016)
• Drove commercial launch for Ability Maintena (aripiprazole LAI) and Jinarc (tolvaptan in ADPKD) in Europe

• Worked on commercial and go-to-market strategy across the London and Singapore offices
• Line management responsibility for team based across London, Shanghai and Singapore offices; successfully set up Singapore and Shanghai offices

Start-up working on a drug delivery device for improving adherence in the treatment of Tuberculosis
• Listed on CNN Money as one of the '6 ideas for changing the world'

Negotiation strategy development for HIV drug prices

Portfolio analysis

Pediatrics, Gynecology and sub-specialties